Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tissue-Drug Binding: Localization of Drugs and its Significance01:24

Tissue-Drug Binding: Localization of Drugs and its Significance

337
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
337
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

3.7K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
3.7K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

265
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
265
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

1.7K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.7K
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

695
While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
695
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.7K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenolic Compounds with PCSK9 Secretion Inhibitory Activities from the Fruits of <i>Liriope spicata</i>.

ACS omega·2026
Same author

Individually Recognized Functional Ingredients of Korean Health Functional Foods: Functional Classification, Regulatory Context, and Clinical Implication.

Nutrients·2026
Same author

Cycloartane-type triterpenoids from Combretum quadrangulare Kurz with PCSK9 secretion inhibitory activities.

Phytochemistry·2024
Same author

Dihydrostilbenes and flavonoids from whole plants of Jacobaea vulgaris.

Phytochemistry·2024
Same author

No Interference of H9 Extract on Trastuzumab Pharmacokinetics in Their Combinations.

International journal of molecular sciences·2023
Same author

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice.

Pharmaceutics·2023

Related Experiment Video

Updated: Dec 22, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.4K

Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes.

Young Hee Choi1

  • 1College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University_Seoul, 32 Dongguk-lo, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, Korea.

Pharmaceutics
|May 7, 2020
PubMed
Summary

Drug-drug interactions (DDIs) involve changes in systemic and tissue drug exposure. Tissue concentrations in the intestine, liver, and kidney significantly impact pharmacokinetic-based DDIs, affecting drug efficacy and toxicity.

Keywords:
drug interactionpharmacokineticssystemic exposuretissue-specific

More Related Videos

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

9.1K
Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

3.2K

Related Experiment Videos

Last Updated: Dec 22, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.4K
Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

9.1K
Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

3.2K

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Drug Interactions

Background:

  • Systemic drug exposure, measured by area under the plasma concentration-time curve (AUC), is traditionally linked to pharmacodynamic (PD) effects like efficacy and toxicity.
  • Drug-drug interactions (DDIs) are primarily evaluated based on changes in systemic drug exposure.
  • Emerging evidence highlights the critical role of drug concentrations within tissues in modulating PD effects.

Purpose of the Study:

  • To review the impact of systemic and tissue exposure changes in DDIs.
  • To discuss the role of transporters and metabolic enzymes in mediating DDIs.
  • To emphasize the significance of tissue-specific drug concentrations in pharmacokinetic-based DDIs.

Main Methods:

  • Literature review of recent reports on drug transporters and metabolic enzymes involved in DDIs.
  • Analysis of studies examining changes in systemic drug exposure (AUC) during DDIs.
  • Evaluation of research focusing on drug concentrations within specific tissues (intestine, liver, kidney).

Main Results:

  • Systemic exposure changes are a key factor in DDIs, influencing drug efficacy and toxicity.
  • Tissue drug concentrations, particularly in the intestine, liver, and kidney, are critical determinants of DDIs.
  • Transporter and metabolic enzyme activity significantly mediates these exposure changes.

Conclusions:

  • Tissue drug concentrations are as important as systemic exposure in understanding DDIs.
  • Pharmacokinetic-based DDIs are significantly influenced by drug levels in the intestine, liver, and kidney.
  • A comprehensive evaluation of DDIs requires consideration of both systemic and tissue drug disposition.